Literature DB >> 17088403

Acetaminophen recruits spinal p42/p44 MAPKs and GH/IGF-1 receptors to produce analgesia via the serotonergic system.

Jérôme Bonnefont1, Laurence Daulhac, Monique Etienne, Eric Chapuy, Christophe Mallet, Lemlih Ouchchane, Christiane Deval, Jean-Philippe Courade, Marc Ferrara, Alain Eschalier, Eric Clottes.   

Abstract

The mechanism of action of acetaminophen is currently widely discussed. Direct inhibition of cyclooxygenase isoforms remains the commonly advanced hypothesis. We combined behavioral studies with molecular techniques to investigate the mechanism of action of acetaminophen in a model of tonic pain in rats. We show that acetaminophen indirectly stimulates spinal 5-hydroxytryptamine (5-HT)1A receptors in the formalin test, thereby increasing transcript and protein levels of low-affinity neurotrophin receptor, insulin-like growth factor-1 (IGF-1) receptor alpha subunit, and growth hormone receptor and reducing the amount of somatostatin 3 receptor (sst3R) mRNA. Those cellular events seem to be important for the antinociceptive activity of acetaminophen. Indeed, down-regulation of sst3R mRNA depends on acetaminophen-elicited, 5-HT1A receptor-dependent increase in neuronal extracellular signal-regulated kinase 1/2 (ERK1/2) activities that mediate antinociception. In addition, spinal growth hormone (GH) and IGF-1 receptors would also be involved in the antinociceptive activity of the analgesic at different degrees. Our results show the involvement of specific 5-HT1A receptor-dependent cellular events in acetaminophen-produced antinociception and consequently indicate that inhibition of cyclooxygenase activities is not the exclusive mechanism involved. Furthermore, we propose that the mechanisms of 5-HT1A receptor-elicited antinociception and the role of the spinal ERK1/2 pathway in nociception are more intricate than suspected so far and that the GH/IGF-1 axis is an interesting new player in the regulation of spinal nociception.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17088403     DOI: 10.1124/mol.106.025775

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  11 in total

1.  Primate-specific RFPL1 gene controls cell-cycle progression through cyclin B1/Cdc2 degradation.

Authors:  J Bonnefont; T Laforge; O Plastre; B Beck; S Sorce; C Dehay; K-H Krause
Journal:  Cell Death Differ       Date:  2010-08-20       Impact factor: 15.828

Review 2.  Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?

Authors:  Andreas Straube; Bernhard Aicher; Bernd L Fiebich; Gunther Haag
Journal:  BMC Neurol       Date:  2011-03-31       Impact factor: 2.474

3.  Enhanced analgesic effects of nefopam in combination with acetaminophen in rodents.

Authors:  Qian Li; Quankun Zhuang; Yaru Gu; Cailing Dai; Xiaoxiao Gao; Xiaomin Wang; Huimin Wen; Xin Li; Yuyang Zhang
Journal:  Biomed Rep       Date:  2017-12-18

Review 4.  Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition.

Authors:  May Hamza; Raymond A Dionne
Journal:  Curr Mol Pharmacol       Date:  2009-01       Impact factor: 3.339

5.  Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study.

Authors:  Antonio Gatti; Alessandro Fabrizio Sabato; Annalisa Carucci; Laura Bertini; Massimo Mammucari; Roberto Occhioni
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 6.  The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings.

Authors:  Garry G Graham; Michael J Davies; Richard O Day; Anthoulla Mohamudally; Kieran F Scott
Journal:  Inflammopharmacology       Date:  2013-05-30       Impact factor: 4.473

Review 7.  Intravenous paracetamol (acetaminophen).

Authors:  Sean T Duggan; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Interindividual variation in gene expression responses and metabolite formation in acetaminophen-exposed primary human hepatocytes.

Authors:  Marlon J A Jetten; Ainhoa Ruiz-Aracama; Maarten L J Coonen; Sandra M Claessen; Marcel H M van Herwijnen; Arjen Lommen; Joost H M van Delft; Ad A C M Peijnenburg; Jos C S Kleinjans
Journal:  Arch Toxicol       Date:  2015-06-24       Impact factor: 5.153

9.  Identification of the cerebral effects of paracetamol in healthy subjects: an fMRI study.

Authors:  Olivier De Coster; Patrice Forget; Johan De Mey; Peter Van Schuerbeek; Jan Poelaert
Journal:  Br J Pain       Date:  2019-06-04

10.  The brain signature of paracetamol in healthy volunteers: a double-blind randomized trial.

Authors:  Gisèle Pickering; Adrian Kastler; Nicolas Macian; Bruno Pereira; Romain Valabrègue; Stéphane Lehericy; Louis Boyer; Claude Dubray; Betty Jean
Journal:  Drug Des Devel Ther       Date:  2015-07-23       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.